Mills GB - Search Results

1

Erratum to: Modeling precision treatment of breast cancer.

Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, Van't Veer LJ, Spellman PT, Gray JW. Daemen A, et al. Among authors: mills gb. Genome Biol. 2015 May 12;16(1):95. doi: 10.1186/s13059-015-0658-5. Genome Biol. 2015. PMID: 25962591 Free PMC article.

2

NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas.

Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC Jr. Yu Y, et al. Among authors: mills gb. Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):214-9. doi: 10.1073/pnas.96.1.214. Proc Natl Acad Sci U S A. 1999. PMID: 9874798 Free PMC article.

3

PIK3CA is implicated as an oncogene in ovarian cancer.

Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. Shayesteh L, et al. Among authors: mills gb. Nat Genet. 1999 Jan;21(1):99-102. doi: 10.1038/5042. Nat Genet. 1999. PMID: 9916799

4

Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.

Mills GB, Lu Y, Kohn EC. Mills GB, et al. Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10031-3. doi: 10.1073/pnas.191379498. Proc Natl Acad Sci U S A. 2001. PMID: 11526226 Free PMC article. No abstract available.

5

The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.

Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, Jaffe R, Gray J. Mills GB, et al. Semin Oncol. 2001 Oct;28(5 Suppl 16):125-41. doi: 10.1016/s0093-7754(01)90290-8. Semin Oncol. 2001. PMID: 11706404 Review.

6

Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Hu L, et al. Among authors: mills gb. Cancer Res. 2002 Feb 15;62(4):1087-92. Cancer Res. 2002. PMID: 11861387

7

Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway.

Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB. Fang X, et al. Among authors: mills gb. Mol Cell Biol. 2002 Apr;22(7):2099-110. doi: 10.1128/MCB.22.7.2099-2110.2002. Mol Cell Biol. 2002. PMID: 11884598 Free PMC article.

8

Specific keynote: molecular therapeutics in ovarian cancer.

Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC Jr, Gray J. Mills GB, et al. Gynecol Oncol. 2003 Jan;88(1 Pt 2):S88-92; discussion S93-6. doi: 10.1006/gyno.2002.6692. Gynecol Oncol. 2003. PMID: 12586094 Review. No abstract available.

9

Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.

Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Mills GB, et al. Semin Oncol. 2003 Oct;30(5 Suppl 16):93-104. doi: 10.1053/j.seminoncol.2003.08.011. Semin Oncol. 2003. PMID: 14613030 Review.

10

Targeting PI3K-AKT pathway for cancer therapy.

Lu Y, Wang H, Mills GB. Lu Y, et al. Among authors: mills gb. Rev Clin Exp Hematol. 2003 Jun;7(2):205-28. Rev Clin Exp Hematol. 2003. PMID: 14763163 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,149 results

Search Page

Filters